# Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

> **NCT01256580** · NA · WITHDRAWN · sponsor: **Massachusetts Eye and Ear Infirmary**

## Conditions studied

- Choroidal Neovascularization
- Myopia
- Punctate Inner Choroidopathy (PIC)
- Multifocal Choroiditis
- Ocular Histoplasmosis Syndrome
- Central Serous Chorioretinopathy (CSC)
- Angioid Streaks
- Trauma, or Hereditary Eye Diseases

## Interventions

- **DRUG:** Bevacizumab (Avastin; Genentech, Inc.)
- **DRUG:** Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy

## Key facts

- **NCT ID:** NCT01256580
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-08
- **Primary completion:** 2013-03
- **Final completion:** 2013-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of eligible subjects.
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256580, "Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01256580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*